Biotech Stocks Facing FDA Decision In January

The FDA decision on Tesaro's intravenous formulation of Rolapitant, developed for the prevention of chemotherapy-induced nausea and vomiting, is scheduled for January 11, 2017.

from RTT - Biotech http://ift.tt/2iHTiwq
via IFTTT